Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PTIE's Cash to Debt is ranked higher than
94% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. PTIE: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PTIE' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Interest Coverage No Debt
PTIE's Interest Coverage is ranked higher than
90% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTIE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PTIE' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: 23.74
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -29.22
PTIE's ROE (%) is ranked higher than
51% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. PTIE: -29.22 )
Ranked among companies with meaningful ROE (%) only.
PTIE' s 10-Year ROE (%) Range
Min: -72.21  Med: -17.03 Max: 102.69
Current: -29.22
-72.21
102.69
ROA (%) -28.09
PTIE's ROA (%) is ranked lower than
51% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. PTIE: -28.09 )
Ranked among companies with meaningful ROA (%) only.
PTIE' s 10-Year ROA (%) Range
Min: -41.58  Med: -8.55 Max: 58.98
Current: -28.09
-41.58
58.98
ROC (Joel Greenblatt) (%) -8305.40
PTIE's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. PTIE: -8305.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTIE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -38255.38  Med: -998.20 Max: 778.06
Current: -8305.4
-38255.38
778.06
Revenue Growth (3Y)(%) -100.00
PTIE's Revenue Growth (3Y)(%) is ranked lower than
92% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PTIE: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTIE' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 129.5
Current: -100
0
129.5
EBITDA Growth (3Y)(%) 50.00
PTIE's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. PTIE: 50.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PTIE' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.9  Med: 3.75 Max: 50
Current: 50
-18.9
50
EPS Growth (3Y)(%) 65.10
PTIE's EPS Growth (3Y)(%) is ranked higher than
96% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. PTIE: 65.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PTIE' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.1  Med: 2.95 Max: 65.1
Current: 65.1
-32.1
65.1
» PTIE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

PTIE Guru Trades in Q3 2014

First Eagle Investment 5,050,837 sh (+12.87%)
Jim Simons 350,087 sh (+4.79%)
First Eagle Investment 4,643,950 sh (unchged)
First Eagle Investment 4,643,950 sh (unchged)
Mario Gabelli 100,000 sh (-33.33%)
» More
Q4 2014

PTIE Guru Trades in Q4 2014

First Eagle Investment 5,684,510 sh (+12.55%)
First Eagle Investment 5,684,510 sh (+12.55%)
Jim Simons 304,387 sh (-13.05%)
Mario Gabelli 85,000 sh (-15.00%)
» More
Q1 2015

PTIE Guru Trades in Q1 2015

Jim Simons 338,687 sh (+11.27%)
First Eagle Investment 5,684,510 sh (unchged)
Mario Gabelli 70,000 sh (-17.65%)
» More
Q2 2015

PTIE Guru Trades in Q2 2015

George Soros 21,700 sh (New)
Louis Moore Bacon 50,000 sh (New)
Jim Simons 519,687 sh (+53.44%)
First Eagle Investment 5,684,510 sh (unchged)
Mario Gabelli 65,000 sh (-7.14%)
» More
» Details

Insider Trades

Latest Guru Trades with PTIE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 15.20
PTIE's Forward P/E is ranked higher than
76% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. PTIE: 15.20 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.33
PTIE's P/B is ranked higher than
73% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. PTIE: 2.33 )
Ranked among companies with meaningful P/B only.
PTIE' s 10-Year P/B Range
Min: 1.55  Med: 4.12 Max: 15.03
Current: 2.33
1.55
15.03
Current Ratio 20.69
PTIE's Current Ratio is ranked higher than
91% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. PTIE: 20.69 )
Ranked among companies with meaningful Current Ratio only.
PTIE' s 10-Year Current Ratio Range
Min: 5.33  Med: 10.10 Max: 61.08
Current: 20.69
5.33
61.08
Quick Ratio 20.69
PTIE's Quick Ratio is ranked higher than
91% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. PTIE: 20.69 )
Ranked among companies with meaningful Quick Ratio only.
PTIE' s 10-Year Quick Ratio Range
Min: 5.33  Med: 10.10 Max: 61.08
Current: 20.69
5.33
61.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.32
PTIE's Price/Net Cash is ranked higher than
88% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. PTIE: 2.32 )
Ranked among companies with meaningful Price/Net Cash only.
PTIE' s 10-Year Price/Net Cash Range
Min: 1.08  Med: 4.16 Max: 30.22
Current: 2.32
1.08
30.22
Price/Net Current Asset Value 2.32
PTIE's Price/Net Current Asset Value is ranked higher than
86% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. PTIE: 2.32 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PTIE' s 10-Year Price/Net Current Asset Value Range
Min: 1.06  Med: 4.06 Max: 11.83
Current: 2.32
1.06
11.83
Price/Tangible Book 2.29
PTIE's Price/Tangible Book is ranked higher than
78% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. PTIE: 2.29 )
Ranked among companies with meaningful Price/Tangible Book only.
PTIE' s 10-Year Price/Tangible Book Range
Min: 1.02  Med: 3.98 Max: 11.43
Current: 2.29
1.02
11.43
Price/Projected FCF 3.69
PTIE's Price/Projected FCF is ranked lower than
51% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. PTIE: 3.69 )
Ranked among companies with meaningful Price/Projected FCF only.
PTIE' s 10-Year Price/Projected FCF Range
Min: 0.72  Med: 2.46 Max: 68.6
Current: 3.69
0.72
68.6
Earnings Yield (Greenblatt) (%) -24.68
PTIE's Earnings Yield (Greenblatt) (%) is ranked lower than
81% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. PTIE: -24.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTIE' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -25.94  Med: 13.40 Max: 754.5
Current: -24.68
-25.94
754.5

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 5 40 70
EPS($) -0.30 -0.70 -0.35 -0.05
EPS without NRI($) -0.30 -0.70 -0.35 -0.05

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PX9.Germany,
Pain Therapeutics Inc a Delaware corporation was incorporated in May 1998. The Company is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Its drug candidate is called REMOXY. REMOXY is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. REMOXY is a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. The Company owns all commercial rights to its pipeline of drug candidates in oncology and hematology. It relies on a limited number of third-party manufacturers to formulate, manufacture, fill, label, ship or store all of its drug candidates. The company's strategies include Focus on Clinical Development Stage Products. It believes this focus will enable the company to generate product revenues earlier than if it was focused on early-stage research and discovery activities; Retain Significant Rights to Drugs: It currently retain worldwide commercialization rights to all of its technology and drug candidates in all markets and indications, except for REMOXY and certain other abuse-resistant drugs. The Company has an exclusive, worldwide Development and License Agreement, or the Durect Agreement, with Durect Corporation, or Durect, to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Companies that currently sell generic or proprietary opioid formulations include, but are not limited to, Roxane Laboratories, Purdue Pharma, Pfizer, Abbott Laboratories, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for PTIE

Headlines

Articles On GuruFocus.com
Wednesday Pre-Market Insights: GEVO, WPZ, HDP, PTIE May 13 2015 
Eveillard's First Eagle Increases 2 Positions Sep 11 2014 
Morning Coffee: Real-Time Picks May 14 2014 
Pain Therapeutics Reports Operating Results (10-K) Feb 03 2011 
Pain Therapeutics Reports Operating Results (10-Q) Oct 29 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 50,000 Shares Oct 04 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 28,597 Shares Sep 08 2010 
Pain Therapeutics (ptie) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 21,403 Shares Sep 02 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 22,391 Shares Aug 04 2010 
Pain Therapeutics Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
PAIN THERAPEUTICS INC Financials Jul 29 2015
10-Q for Pain Therapeutics, Inc. Jul 25 2015
Pain Therapeutics reports 2Q loss Jul 23 2015
Pain Therapeutics reports 2Q loss Jul 23 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Jul 23 2015
Pain Therapeutics Reports Q2 2015 Financial Results Jul 23 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events Jul 09 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events Jun 29 2015
Cantor Analyst: Durect Is Worth $3/Share, So Buy It Jun 24 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 11 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 14 2015
5 New Biotech Developments Worth Watching May 13 2015
Why This Study May Have Saved Pain Therapeutics May 12 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events May 12 2015
PAIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 08 2015
Pain Therapeutics reports 1Q loss May 07 2015
Pain Therapeutics reports 1Q loss May 07 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition May 07 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events May 06 2015
PAIN THERAPEUTICS INC Files SEC form 10-K, Annual Report Feb 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK